Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma

Clark, Joseph I.; Hofmeister, Craig C.; Choudhury, AK; Matz, Gregory J.; Collins, Sharon L.; Bastian, Robert W.; Melian, Edward; Emami, Bahman; Petruzzelli, Guy J.

doi:10.1002/1097-0142(20011101)92:9<2334::aid-cncr1580>3.0.co;2-3

Cited by 54 publications

(33 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this assay, the optical density (OD) values represented the absorption of formazan dissolved by dimethyl sulfoxide (DMSO) at 570 nm. Cells (5x10 3 per well) were seeded in quintuplicate in a 96-well plate containing 150 µl culture complete medium. After 24 h of incubation, different concentrations of mitoxantrone were added to the designated wells after the addition of FTC (5 and 10 µM).…”

Section: Immunohistochemistrymentioning

confidence: 99%

“…However, for loco-regionally advanced stage HNSCC (stages Ⅲ and Ⅳ), the benefits of surgery are much less apparent as most patients eventually present with recurrence (2). Moreover, approximately two-thirds of these patients have advanced disease with large primary tumors and/ or regional lymph node involvements (T3-4/N2-3 and M0-1) at the time of diagnosis (3). Thus, the conventional treatment for these patients is chemotherapy or radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines

Shen

Dong

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Overexpression of breast cancer resistance protein, the ATP-binding cassette, subfamily G, member2 (BCRP/ABCG2), confers multidrug resistance to tumor cells and often limits the efficacy of chemotherapy. The aim of this study was to investigate the expression and functional activity of ABCG2 in head and neck squamous cell carcinoma (HNSCC) and corresponding cell lines. Immunohistochemistry was performed to investigate the presence of the ABCG2 transporter in HNSCC tissues. Expression of ABCG2 in the Hep-2, Hep-2T, CNE and FaDu cell lines was analyzed by real-time quantitative reverse transcription-polymerase chain reaction and Western blotting at the levels of messenger RNA (mRNA) and protein, respectively. The drug sensitivity of the above four cell lines to mitoxantrone was detected using MTT, and the drug accumulation of mitoxantrone was analyzed by flow cytometry. Positive expression of ABCG2 was detected in 52.04% of the laryngeal cancer samples from 98 patients, in 65% of the 40 hypopharyngeal cancer samples and in 58.82% of the 34 nasopharyngeal cancer samples. The level of expression was found to be correlated with tumor TNM stage (P<0.05) and lymph node metastasis (P<0.01). All four HNSCC cell lines expressed ABCG2 at the mRNA and protein levels. The levels of ABCG2 expression in the four cell lines were significantly correlated with the function and sensitivity to mitoxantrone. The addition of fumitremorgin C at a concentration of 5 µM to mitoxantrone treatment caused a varied increase in mitoxantrone accumulation of 1.09-fold, 1.33-fold (P<0.01), 1.4-fold (P<0.01) and 1-fold in the Hep-2, Hep-2T, CNE and FaDu cells, respectively. Expression of ABCG2 varied among the different types of carcinoma tissues and each HNSCC cell line, and it induced multidrug resistance and separation of cancer stem cells attributing to its efflux pump function. Thus, ABCG2 expression may be an unfavorable prognostic factor for HNSCC. Due to the negligible expression and function of ABCG2, we suggest that the FaDu cell line is suitable to be a negative control in studies involving HNSCC. Taken together, ABCG2 is a promising universal biomarker of cancer stem cells and a target gene for HNSCC chemotherapy.

show abstract

Section: Immunohistochemistrymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines

Shen

Dong

et al. 2011

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…For patients who relapse after such treatment, the only curative treatment option is surgical. If this is not possible, as is often the case, platinum-based chemotherapy is frequently used as palliative therapy (Forastiere et al, 1992;Jacobs et al, 1992) Other drugs that have some activity in this tumour type include bleomycin, methotrexate, taxanes, gemcitabine and vinorelbine (Clark et al, 2001;Basaran et al, 2002). However, tumour response rates rarely exceed 30 -35% (Liggett and Forastiere, 1995) and responses are usually of short duration such that the outlook in the setting of recurrent/metastatic disease is poor, with 1-year survival below 30% and median survival only 4 months.…”

mentioning

confidence: 99%

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

et al. 2006

View full text Add to dashboard Cite

To assess the level of activity and toxicity of gefitinib (ZD1839, Iressat) in a population of patients with locally recurrent and/or metastatic head and neck cancer. Patients were recruited into an expanded access programme through the multidisciplinary head and neck clinics at the Royal Marsden and St George's Hospitals. Patients were required to have received at least one course of standard systemic chemotherapy or radiation therapy, or be medically unfit for chemotherapy. Patients were commenced on single-agent gefitinib at a dose of 500 mg day À1 . Clinical, symptomatic and radiological response, time to progression (TTP), survival and toxicity were recorded. A total of 47 patients were enrolled (35 male and 12 female) with a median age of 62 years (range 18 -93 years). The observed clinical response rate was 8% with a disease control rate (complete response, partial response, stable disease) of 36%. In all, 34% of patients experienced an improvement in their symptoms. The median TTP and survival were 2.6 and 4.3 months, respectively. Acneiform folliculitis was the most frequent toxicity observed (76%) but the majority of cases were grade 1 or 2. Only four patients experienced grade 3 toxicity of any type (all cases of folliculitis). Gefitinib was well tolerated and yielded symptomatic improvement in one-third of patients. However, this agent appeared to possess limited antitumour activity in this group of patients with head and neck cancer in whom the objective response rate, median TTP and survival were all lower than has been reported in a previous study.

show abstract

“…[62][63][64][65][66] For patients with excellent performance status, normal end-organ function, and no significant comorbidities, combination chemotherapy regimens are recommended. Most frequently used are two-drug combination regimens (cisplatin þ 5-FU, 67,68 cisplatin þ paclitaxel, 69,70 cisplatin þ docetaxel, [71][72][73][74] carboplatin þ taxane [75][76][77] ) and are associated with improved response rates compared with single agent, but they are also associated with increased toxicity and no statistically significant survival benefit.…”

Section: Chemotherapy In Metastatic Diseasementioning

confidence: 99%

The Role of Chemotherapy in the Management of Patients with Head and Neck Cancer

Savvides

2010

Seminars in Plastic Surgery

View full text Add to dashboard Cite

Recent advances in the management of patients with head and neck cancer point to an expanding role of chemotherapy, resulting in an increased involvement of the medical oncologist in the multidisciplinary care of these patients. This review focuses on patients with squamous cell carcinoma of the oral cavity, pharynx, and larynx. A comprehensive review of the clinical trial data that have defined new standards of care and a detailed presentation of widely used chemotherapeutic regimens, including both cytotoxic and molecularly targeted agents, are presented. Information on human papilloma virusassociated squamous cell cancer of the head and neck is presented, and implications in the clinical management of this subgroup of patients based on the epidemiologic and pathologic characteristics are discussed.KEYWORDS: Cancer of the head and neck, chemotherapy, squamous cell carcinoma Approximately 48,000 new cases of head and neck cancer were expected in the United States in 2009 alone, 1 and more than 600,000 new cases will be diagnosed worldwide. Head and neck cancer accounts for 3 to 4% of all cancer diagnoses in Western countries, 2,3 and its incidence is higher in southeast Asia and in Africa where it accounts for 8 to 10% of all cancers. 4 Overall, head and neck cancer represents the eighth most common cause of cancer death.Historically, treatment of patients with squamous cell carcinoma of the head and neck (SSCHN) has primarily been driven by surgical interventions and continued advances in radiation therapy (RT) treatment planning and delivery. In this setting of complex treatment algorithms, recent advances in the management of patients with head and neck cancer point to an expanding role of chemotherapy and therefore an increased involvement of the medical oncologist in the multidisciplinary care of these patients.The scope of this review is to provide a comprehensive description of expanding chemotherapeutic options, including both cytotoxic and molecularly targeted agents, that are applicable to patients diagnosed with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx. Data on patients diagnosed with cancer of the nasopharynx will be presented separately because of its distinct etiology, pathology, and response to treatment modalities.Chemotherapy alone does not have curative potential. As a result, it does not have a defined role

show abstract

Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma

Cited by 54 publications

References 10 publications

Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines

Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

The Role of Chemotherapy in the Management of Patients with Head and Neck Cancer

Contact Info

Product

Resources

About